Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Common Equity (2022 - 2025)

Oramed Pharmaceuticals' Common Equity history spans 4 years, with the latest figure at $199.7 million for Q4 2025.

  • For Q4 2025, Common Equity changed N/A year-over-year to $199.7 million; the TTM value through Dec 2025 reached $199.7 million, changed N/A, while the annual FY2025 figure was $199.7 million, N/A changed from the prior year.
  • Common Equity reached $199.7 million in Q4 2025 per ORMP's latest filing, down from $202.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $202.3 million in Q3 2025 to a low of $139.9 million in Q1 2025.
  • Average Common Equity over 4 years is $161.6 million, with a median of $153.6 million recorded in 2025.
  • The largest YoY upside for Common Equity was 30.1% in 2025 against a maximum downside of 15.58% in 2025.
  • A 4-year view of Common Equity shows it stood at $151.2 million in 2022, then grew by 7.76% to $162.9 million in 2023, then fell by 4.53% to $155.5 million in 2024, then rose by 28.43% to $199.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Common Equity are $199.7 million (Q4 2025), $202.3 million (Q3 2025), and $153.6 million (Q2 2025).